First clinical study of a pegylated diabody (124)I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers

Through protein engineering and a novel pegylation strategy, a diabody specific to tumor-associated glycoprotein 72 (TAG-72) (PEG-AVP0458) has been created to optimize pharmacokinetics and bioavailability to tumor. We report the preclinical and clinical translation of PEG-AVP0458 to a first-in-human...

Descripción completa

Detalles Bibliográficos
Autores principales: Scott, Andrew M., Akhurst, Timothy, Lee, Fook-Thean, Ciprotti, Marika, Davis, Ian D., Weickhardt, Andrew J., Gan, Hui K., Hicks, Rodney J., Lee, Sze Ting, Kocovski, Pece, Guo, Nancy, Oh, Maggie, Mileshkin, Linda, Williams, Scott, Murphy, Declan, Pathmaraj, Kunthi, O'Keefe, Graeme J., Gong, Sylvia J., Pedersen, John S., Scott, Fiona E., Wheatcroft, Michael P., Hudson, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545991/
https://www.ncbi.nlm.nih.gov/pubmed/33052222
http://dx.doi.org/10.7150/thno.49422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545991/
https://www.ncbi.nlm.nih.gov/pubmed/33052222
http://dx.doi.org/10.7150/thno.49422

Ejemplares similares